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Abstract
I In nt tr ro od du uc ct ti io on n: :   Sickle cell disease (SCD) is an inflammatory condition with an
increase in the adhesion of sickled erythrocytes, and it is a potential cause of
vaso-occlusive episodes, an event related to clinical manifestations, morbidity
and mortality. The cystathionine beta-synthase enzyme gene (CBS) and the
methylenetetrahydrofolate reductase enzyme gene (MTHFR) are risk factors for
thromboembolic disorders. This study evaluated the frequency of the 844ins68
CBS and C677T MTHFR gene polymorphisms and their possibility to be risk
factors for vaso-occlusive crises.
M Ma at te er ri ia al l   a an nd d   m me et th ho od ds s: :   In total 91 blood samples from SCD patients were studied
by PCR-RFLP and PCR-allele-specific, for the SCD genotype confirmation and
polymorphism identification.
R Re es su ul lt ts s: :   The presence of clinical manifestations related to vaso-occlusive crises
were more frequent among patients with the Hb SS genotype (p = 0.007). 
The CBS enzyme gene was three times more frequent (p = 0.011) among patients
with vaso-occlusive complications. The MTHFR gene mutation frequency showed
no increased risk for vaso-occlusive crises in SCD patients (p = 0.193). The inter  -
action between the two polymorphisms was evaluated in 12.08% of the SCD
patients and doubled the vaso-occlusive disease risk (relative risk: 2.16). 
C Co on nc cl lu us si io on ns s: :   We conclude that the presence of 844ins68 CBS and C677T MTHFR
gene polymorphism was a risk factor for vaso-occlusive episodes in the SCD
patients evaluated.
K Ke ey y   w wo or rd ds s: :   sickle cell disease, polymorphism, cystathionine beta-synthase,
methylenetetrahydrofolate reductase.
Introduction
As described in the literature, elevated levels of homocysteine (HCy)
are associated with a higher risk of cardiovascular diseases and venous
thrombosis [1, 2]. However, the physiological mechanisms that explain this
association are still not completely clear. HCy levels can be genetic
determined, but can also be affected by environmental factors, such as
lifestyle, age, gender, nutrition, physical activity, and drugs or cigarettes.
In most cases, an abnormal level of HCy is not caused by one isolated
factor; instead, it is frequently a result of a combination of factors [3].
Therefore, it is important to understand how, exactly, genetic factors are
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involved in the production of plasma HCy. It is also
important to promote the prevention and treatment
of thrombotic diseases that result from high levels
of homocysteine and how genetic mutations in the
enzymes involved in the metabolism of HCy, such
as 844ins68 on the cystathionine-ʲ-synthase (CBS)
and  C677T  on  the  methylenetetrahydrofolate
reductase (MTHFR), can contribute to higher levels
of plasma HCy [4-6]. 
The 844ins68 mutation on the CBS gene, in
homozygous or heterozygous state, is considered
an independent risk factor for artery occlusion. The
mutation on the MTHFR gene also causes lower
enzyme activity, which results in higher levels 
of serum HCy [7]. Furthermore, MTHFR gene alter  -
ations increase the risk of vascular diseases and
DNA hypomethylation, and can also affect and
influence cell adhesion and nitric oxide activation
[8]. Previous studies have stated that the co-exi  -
stence of the genotype C677TT on the MTHFR gene
and the 844ins68 variant on the CBS gene, are
significant for patients with thrombosis of unknown
origin. This finding suggests that the presence of
these altered genotypes puts the individual at a risk
of vaso-occlusive crises [9]. 
Sickle cell disease is an inflammatory condition
in which mediator-enzymes activate the endothelial
cells and increase the adhesion of platelets, white
blood cells, and sickle-shaped red blood cells to the
endothelium, which can lead to vaso-occlusive
episodes  [10].  The  clotting  of  both  deep  and
superficial veins is the most important factor in the
sickle cell disease physiopathology, and can be used
to explain some of the clinical manifestations, as
well as the morbidity and mortality [11]. The aim of
this  study  was  to  evaluate  the  frequency  of
844ins68 on the CBS gene and C677T on the
MTHFR gene polymorphisms and their correlation
with vaso-occlusive episodes in patients with sickle
cell disease from Brazil. 
Material and methods
P Pa at ti ie en nt ts s’ ’   d da at ta a
This  study  was  approved  by  the  Ethical
Committee from the UNESP-IBILCE and the Clinical
Hospital from the Goiás Federal University (UFG).
Analyses  were  conducted  for  91  sickle  cell
patients from the UFG Clinical Hospital, 51 women
and 40 men aged 19-59 years. Forty-nine patients
used Hydroxyurea. All the patients studied received
a prophylactic treatment with folic acid of 5 mg/day
since the SCD diagnosis. Through analysis of the
patients’ records, five presented ischemic stroke,
eleven experienced ischemic bone necrosis, five had
priapism, four had malleolar ulcers, six presented
osteomyelitis, six experienced complications during
pregnancy, sixteen had retinopathy, two had alveolar
hemorrhages, and four had splenic infarction. All of
these vaso-occlusive complications were confirmed
by the patient’s hematologist. There is no difference
between male and female vaso-occlusive events
except for the priapism in males. 
All  patients  participated  in  the  ambulatory
evaluation  and  5 ml  of  blood  samples  were
collected with EDTA anticoagulants after filling
a consent form. Patients were genotyped for the
Sickle Cell Disease [12]. DNA was extracted from
peripheral  blood  lymphocytes  and  isolated  by
phenol-chloroform methodology [13].
G Ge en no ot ty yp pi in ng g
The mutations in the globin genes were per  for  -
med by PCR- RFLP [14] and PCR-EA [15] to determine
the sickle cell disease genotype (Hb SS, Hb SC or
Hb S/Beta thal.). The CBS polymorphisms were
detected using PCR as previously described [6]. The
MTHFR  polymorphisms  were  detected  using 
PCR-RFLP [16]. The fragment amplified was digested
using HinfI Fast Enzyme Restrictionﾮ (Fermentas)
and separated in 2% agar gel. These methods are
able to detect all three possible genotypes for the
globin gene, CBS and MTHFR polymorphism: homo  -
zygous wild type, heterozygous variant type and
homozygous variant type. Figure 1 shows a picture
of agarose gel for MTHFR polymorphism evaluated
in SCD patients.
We applied the ˇ2 test with a level of significance
of 90% (p = 0.05) and Yates’ correction at n < 5 to
compare the polymorphism frequencies. Calcu  la  -
tions for relative risk were made, and the ˇ2 test
was used to verify the statistical significance. 
The cal  culations were made using the Statistica
soft  ware, version 7.0.
Results
Of all 91 sickle cell disease patients evaluated,
48 presented the Hb SS genotype, 20 Hb SC, and
F Fi ig gu ur re e   1 1. .   Agarose gel of MTHFR polymorphism eva  -
lu  ated in SCD patients. Samples 1, 2 and 6 show
a hete  rozygote profile. Polymorphism analysis of 
the  MTHFR  allele:  HinfI-digest  PCR  fragments 
(175 bp) and the normal allele (198 bp)
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23 Hb S/Beta Thalassemia (IVS 1-110). The corre  -
lation between the SCD genotypes and the occu  -
rrence of vaso-occlusive event was significant 
(ˇ2 = 9.969; GL = 2; p = 0.007), with the majority
of the cases occurring in patients with the Hb SS
genotype, as shown in Table I. The beta globin
haplotypes evaluated shown prevalence of the
Bantu/Benin heterozygous profile, as expected for
the Brazilian population. Clinical observations and
laboratory exams revealed that 33.33% of the 
SCD patients who received Hydroxyurea had a sig  -
nificant increase in Hb F concentration, despite the
haplotype. This increase was more than 15% in
relation to the initial treatment, particularly in Hb
SS patients. 
The  heterozygous  genotype  of  CBS  gene
polymorphism was found in 32.96% of the SCD
patients, and the homozygous variant type was
found in 1.09%. The heterozygous frequency of the
MTHFR gene polymorphism was found in 34.06%,
and the homozygous variant type was found in
2.19%. The allele frequency of CBS variants was
17.58%, and for the MTHFR variants it was 19.23%,
also in Hardy-Weinberg equilibrium. We observed
a significant difference in the CBS polymorphism
presence between Hb SS and Hb S/Beta thal.
genotypes (ˇ2 = 5.219; GL = 1; p = 0.022). However,
when hemoglobin genotypes and the presence of
polymorphisms were evaluated together, we did
not observe a significant difference in the allele CBS
variant frequency (ˇ2 = 3.441; GL = 1; p = 0.064),
neither to the MTHFR polymorphisms (ˇ2 = 0.799;
GL = 1; p = 0.371).
Comparison between vaso-occlusive events and
polymorphism allele frequency showed a significant
difference for the CBS gene (ˇ2 = 6.502; GL = 1; 
p = 0.011). The SCD patients did not show evidence
of major vaso-occlusive events, except for one with
a vascular cerebral accident. This mutation was
approximately  three  times  more  frequent  in
patients  with  clinical  sickle  cell  complications 
(Table II). In the case of the MTHFR gene mutation,
we did not find the same correlation (ˇ2 = 1.698; 
GL = 1; p = 0.193).
The interaction between the two polymorphisms
studied was found in eleven patients (12.08%) and
91% of them presented vaso-occlusive episodes,
which  suggests  a significant  association  that
determines an increased risk of these clinical
complications in these patients (ˇ2 = 8.158; GL = 1;
p = 0.004). The combination between MTHFR and
insertion of 86pb on the CBS gene showed a 100%
increase in the relative risk (RR: 2.16; 95%) for vaso-
occlusive episodes, arterial disease, and/or venous
disease, with a confidence interval (CI) of 0.31-1.68,
as shown in Table III. 
Discussion
The clinical manifestations of sickle cell disease
are more severe in Hb SS genotype [11]. The mani  -
festations can also be influenced by the inheritance
of the beta globin cluster haplotypes associated
with Hb F concentration and differential gene
expression with inhibitory effects on the sickling
process. Patients with Hb F above 20% presented
G Ge en no ot ty yp pe e P Pr re es se en nc ce e   o of f    A Ab bs se en nc ce e   o of f N N = =   9 91 1
v va as so o- -o oc cc cl lu us si iv ve e    v va as so o- -o oc cc cl lu us si iv ve e
e ev ve en nt ts s   ( (n n = =   5 59 9) ) e ev ve en nt ts s   ( (n n = =   3 32 2) )
SS 34 14 48
S/Beta Thal 8 15 23
SC 12 8 20
ˇ2 ˇ2 = 9.969; 
DF = 2; p = 0.007
ˇ2 ˇ2 = 8.380; 
DF = 8; p = 0.015
T Ta ab bl le e   I I. .   Presence or absence of vaso-occlusive events
in relation to the globin gene genotypes
ˇ2 – Chi-Square test, DF – degree of freedom, p ≤ 0.05
P Pr re es se en nc ce e   o of f   t th he e   v va as so o- -o oc cc cl lu us si iv ve e    A Ab bs se en nc ce e   o of f   t th he e   v va as so o- -o oc cc cl lu us si iv ve e   
e ev ve en nt t   ( (n n   = =   5 59 9) )       e ev ve en nt t   ( (n n = =   3 32 2) )   
G Ge en ne es s A Al ll le el le e   n nu um mb be er r A Al ll le el le e   f fr re eq qu ue en nc cy y A Al ll le el le e   n nu um mb be er r A Al ll le el le e   f fr re eq qu ue en nc cy y ˇ2 2 D DF F p p
W W M M W W M M W W M M W W M M
MTHFR 92 26 0.78 0.22 55 9 0.86 0.14 1.698 1 0.193
CBS 91 27 0.77 0.23 59 5 0.92 0.08 6.502 1 0 0. .0 01 11 1* *
ˇ2 – Chi-Square test, DF – degree of freedom, p  ≤ 0.05
T Ta ab bl le e   I II I. .   Allele frequency for the CBS and MTHFR polymorphisms compared to the presence or absence of the vaso-
occlusive event in SCD patients (n = 91)
M MT TH HF FR R/ /C CB BS S    V Va as so o- -o oc cc cl lu us si iv ve e   e ev ve en nt t T To ot ta al l
i in nt te er ra ac ct ti io on n Y Ye es s    N No o
Presence 10 1 11
Absence 16 22 38
Total 26 23 49
Chi-Square test (ˇ2 = 8.158, GL = 1, 95% IC: 0.31-1.68, p = 0.004) 
T Ta ab bl le e   I II II I. . MTHFR and CBS polymorphism interaction
and risk factor for the vaso-occlusive events in SCD
patients (n = 49)100 Arch Med Sci 1, February / 2011
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mild clinical manifestations [17]. In this study, SCD
patients who received Hydroxyurea confirm the
results of the literature that fewer transfusions are
needed when they receive Hydroxyurea treatment,
despite the haplotypes inherited, mainly because
of the admixture of the Brazilian populations. 
The  relation  between  the  presence  of  the
insertion of 68pb on the CBS gene and the vaso-
occlusive events was significant in the SCD patients
studied. The literature reports that this mutation is
a risk factor for venous thromboembolism and
premature arteriosclerotic disease in other groups
of patients, but not for sickle cell patients [6]. The
interaction  between  the  two  polymorphisms
evaluated  in  this  study,  which  were  inherited
together, was associated with a 100% increased
risk of developing a vaso-occlusive episode in SCD
patients as supported by the literature [18, 19]. 
The frequency of the MTHFR polymorphism in
SCD patients did not show an increased risk of
a vaso-occlusive event and confirms findings of
Morielli et al. [18] concerning the Brazilian popu  -
lation, but contradicts the literature about other
similar populations [7, 8]. It is important to note
that studies suggest that these polymorphisms,
which affect folate metabolism and which are risk
factors for vaso-occlusive patients, have different
effects within different populations, with evidence
of a gene-gene and gene-nutrient interaction [19].
The literature shows that 200 ﾵg of folic acid
a day can reduce the concentration of homo  cys  -
teine by up to 60%, and a daily dose of 400 ﾵg
is associated with an up to 90% reduction in the
concentration of homocysteine [18]. Folic acid can
be a prophy  lactic therapy for those patients with
poly  morphisms on the MTHFR gene. It lowers
homo  cysteine levels, and, consequently, the occu  -
rrence of vaso-occlusive complications like throm  -
bosis and cerebral vascular accidents. The lack of
vaso-occlusive complications in these SCD pa  -
tients can be attributed to therapies involving folic
acid. 
Although the majority of these SCD patients 
do  not  present  serious  vaso-occlusive  events,
unobserved complications are the leading cause of
chronic organ and tissue damage. However, the
frequency of clinically detectable vaso-occlusive
crises should not be the unique parameter for
evaluating the gravity of sickle cell disease, and it
cannot serve as a reliable parameter for effective
therapy in every patient. When we consider the
shortage of studies involving Brazilians of African
descent related to the frequency and interaction of
the genetic polymorphisms evaluated, we conclude
that the presence of the 844ins68 mutation on the
CBS gene is a risk factor for vaso-occlusive episodes
in SCD patients. The results obtained will contribute
to improvement of the understanding of the clinical
manifestations experienced by these patients, and
will also offer more information to the use of
prophylactic treatments and certain therapies. 
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